Caroline G. Ploeger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline G. Ploeger has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Burger
Utah Fertility Center, Pleasant Grove, UT 84062, USA
1 shared publication - Ammon Bayles
Utah Fertility Center, Pleasant Grove, UT 84062, USA
1 shared publication Carolina Carvalho Soares Valentim
Department of Ophthalmology and Visual Sciences, University of Louisville and
1 shared publication- Carolina Carvalho Soares Valentim
Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, Kentucky
1 shared publication Cole Wyatt
1 shared publication- Eyas M. Hattab
Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, USA
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-15
Biosimilars in Adult and Pediatric Noninfectious Uveitis
Purpose: To review and compare the efficacy and safety of adult and pediatric biologic biosimilar use for the treatment of noninfectious uveitis (NIU). Methods: A review of the literature from inception to December 2025 was conducted using Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify studies that included data or discussion on the use of biosimilar biologic agents for adult and/or pediatric NIU. Articles related to these topics were included and discussed within this review. Results: Most studies examining biosimilar use in adult and pediatric noninfectious uveitis have evaluated the efficacy and safety of anti-tumor necrosis factor alpha (anti-TNF-α) agents, primarily adalimumab and infliximab biosimilars. Identified studies in both adults and children largely consisted of two designs: those comparing reference biologics with biosimilars and switch studies assessing outcomes following conversion to biosimilar therapy. Golimumab, certolizumab pegol, tocilizumab, sarilumab, and rituximab reference biologic studies offer promising results for treatment of NIU, but clinical trials evaluating biosimilar biologics lack in the literature. Compared with adult populations, pediatric cohorts treated with biosimilars for NIU are underrepresented in the literature. Conclusion: Current evidence suggests that adalimumab and infliximab biosimilars are effective and safe in comparison to reference biologics for treatment of NIU in the adult and pediatric populations. Expanded investigation in pediatric cohorts, including prospective clinical trials and inclusion of other biosimilar biologic agents are needed to address current gaps in evidence and to inform clinical decision-making.
- 1 March 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-15
Open AccessBiosimilars in Adult and Pediatric Noninfectious Uveitis
Purpose: To review and compare the efficacy and safety of adult and pediatric biologic biosimilar use for the treatment of noninfectious uveitis (NIU). Methods: A review of the literature from inception to December 2025 was conducted using Pubmed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science to identify studies that included data or discussion on the use of biosimilar biologic agents for adult and/or pediatric NIU. Articles related to these topics were included and discussed within this review. Results: Most studies examining biosimilar use in adult and pediatric noninfectious uveitis have evaluated the efficacy and safety of anti-tumor necrosis factor alpha (anti-TNF-α) agents, primarily adalimumab and infliximab biosimilars. Identified studies in both adults and children largely consisted of two designs: those comparing reference biologics with biosimilars and switch studies assessing outcomes following conversion to biosimilar therapy. Golimumab, certolizumab pegol, tocilizumab, sarilumab, and rituximab reference biologic studies offer promising results for treatment of NIU, but clinical trials evaluating biosimilar biologics lack in the literature. Compared with adult populations, pediatric cohorts treated with biosimilars for NIU are underrepresented in the literature. Conclusion: Current evidence suggests that adalimumab and infliximab biosimilars are effective and safe in comparison to reference biologics for treatment of NIU in the adult and pediatric populations. Expanded investigation in pediatric cohorts, including prospective clinical trials and inclusion of other biosimilar biologic agents are needed to address current gaps in evidence and to inform clinical decision-making.
- Open Access
- 26 February 2026
- Published by Medtigo in medtigo Journal of Medicine
- Vol. 1 (1) , 1-5
OptiKids Outreach: Enhancing Medical Student Awareness, Engagement, and Support for Pediatric Visual Impairment Through a Patient-Centered Panel
- 26 February 2026
- Published by Medtigo in medtigo Journal of Medicine
- Vol. 1 (1) , 1-5
Open AccessOptiKids Outreach: Enhancing Medical Student Awareness, Engagement, and Support for Pediatric Visual Impairment Through a Patient-Centered Panel
- 9 December 2025
- Published by Taylor & Francis in Orbit
- Vol. 45 (1) , 236-245
Orbital intraosseous hemangioma; report of three cases and systematic review
To present three new cases of primary intraosseous orbital hemangioma (PIOH), including rare lacrimal bone involvement, and to provide an updated systematic review of previously reported cases. We retrospectively reviewed three patients with orbital PIOH from our institution. Clinical, radiographic, histopathologic, and surgical findings were analyzed. A comprehensive systematic review of 84 previously published PIOH cases was performed to assess demographics, anatomic location, imaging, and treatment outcomes. All three patients had firm, progressively enlarging orbital masses. Imaging showed well-circumscribed, expansile lesions confirmed as PIOH histologically. Case 1 involved the zygomatic and sphenoid bones; Case 2, the maxilla and lacrimal bone; and Case 3, the frontal bone. All underwent orbitotomy with subtotal or complete excision and reconstruction. No recurrence was observed at 1-34 month follow-up. In the systematic review, the zygoma (50%) and frontal bone (44%) were most frequently involved. Common symptoms included swelling, proptosis, pain, and globe displacement. CT was the most used imaging modality. Surgical excision, often with preoperative embolization, remains the preferred treatment. Only one recurrence (1.8%) was reported out of the 56 cases with follow-up data. Orbital PIOH is a rare vascular tumor best managed by tailored surgical excision. Our findings and updated systematic review emphasize individualized planning, particularly in rare sites like the lacrimal bone.
- 9 December 2025
- Published by Taylor & Francis in Orbit
- Vol. 45 (1) , 236-245
Orbital intraosseous hemangioma; report of three cases and systematic review
To present three new cases of primary intraosseous orbital hemangioma (PIOH), including rare lacrimal bone involvement, and to provide an updated systematic review of previously reported cases. We retrospectively reviewed three patients with orbital PIOH from our institution. Clinical, radiographic, histopathologic, and surgical findings were analyzed. A comprehensive systematic review of 84 previously published PIOH cases was performed to assess demographics, anatomic location, imaging, and treatment outcomes. All three patients had firm, progressively enlarging orbital masses. Imaging showed well-circumscribed, expansile lesions confirmed as PIOH histologically. Case 1 involved the zygomatic and sphenoid bones; Case 2, the maxilla and lacrimal bone; and Case 3, the frontal bone. All underwent orbitotomy with subtotal or complete excision and reconstruction. No recurrence was observed at 1-34 month follow-up. In the systematic review, the zygoma (50%) and frontal bone (44%) were most frequently involved. Common symptoms included swelling, proptosis, pain, and globe displacement. CT was the most used imaging modality. Surgical excision, often with preoperative embolization, remains the preferred treatment. Only one recurrence (1.8%) was reported out of the 56 cases with follow-up data. Orbital PIOH is a rare vascular tumor best managed by tailored surgical excision. Our findings and updated systematic review emphasize individualized planning, particularly in rare sites like the lacrimal bone.
- 1 November 2025
- Published by SLACK, Inc. in Journal of Pediatric Ophthalmology & Strabismus
- Vol. 62 (6) , e85-e89
Pediatric Giant-Cell Tumor of Bone With Secondary Aneurysmal Bone Cyst Causing Orbital Apex Syndrome
Giant-cell tumors of bone (GCTBs) are benign, expansile lesions usually found in the long bones of young adults. The authors report a pediatric skull base GCTB causing cranial nerve deficits and vision loss. The patient presented with blurry vision, left eye misalignment, headaches, nausea, and vomiting. Imaging revealed a large heterogenous mass invading the anterior cranial fossa floor. Initial histopathology suggested an aneurysmal bone cyst (ABC), and the mass was surgically resected. Four months later, recurrence led to genetic testing, which identified a p.G35W H3F3A mutation, confirming GCTB with secondary ABC of the pituitary fossa causing right compressive optic neuropathy and left orbital apex syndrome. Management included repeat resection and denosumab therapy, achieving radiographic stability with preservation of vision in the right eye, although the optic nerve of the left eye remained atrophic. Given the diagnostic overlap between GCTB and ABC, the authors emphasize the importance of genetic testing for accurate and early diagnosis to enable timely treatment and reduce the risk of recurrence.
- 1 November 2025
- Published by SLACK, Inc. in Journal of Pediatric Ophthalmology & Strabismus
- Vol. 62 (6) , e85-e89
Pediatric Giant-Cell Tumor of Bone With Secondary Aneurysmal Bone Cyst Causing Orbital Apex Syndrome
Giant-cell tumors of bone (GCTBs) are benign, expansile lesions usually found in the long bones of young adults. The authors report a pediatric skull base GCTB causing cranial nerve deficits and vision loss. The patient presented with blurry vision, left eye misalignment, headaches, nausea, and vomiting. Imaging revealed a large heterogenous mass invading the anterior cranial fossa floor. Initial histopathology suggested an aneurysmal bone cyst (ABC), and the mass was surgically resected. Four months later, recurrence led to genetic testing, which identified a p.G35W H3F3A mutation, confirming GCTB with secondary ABC of the pituitary fossa causing right compressive optic neuropathy and left orbital apex syndrome. Management included repeat resection and denosumab therapy, achieving radiographic stability with preservation of vision in the right eye, although the optic nerve of the left eye remained atrophic. Given the diagnostic overlap between GCTB and ABC, the authors emphasize the importance of genetic testing for accurate and early diagnosis to enable timely treatment and reduce the risk of recurrence.
- Open Access
- 19 May 2025
- Published by MDPI AG in Reproductive Medicine
- Vol. 6 (2) , 13
Changes in Sperm Glutathione and Glutathione Redox States Correlate to Poor Sperm Qualitative Measures
Background/Objectives: In the past 50 years, human reproductive capacity has steadily declined with elusive and idiopathic origins. Amongst theorized causes, oxidative stress has been proposed to directly contribute to male infertility. The glutathione (GSH) and glutathione disulfide (GSSG) molecular couple reflect cellular redox environments and are thus reflective of oxidative stress in most cells. Shifting GSH/GSSG redox states to abnormal, more oxidizing conditions can disrupt normal cellular activities. This study explores the correlation between the GSH/GSSG redox system and factors involved in male infertility, including sperm quality, specifically sperm motility and total count. Methods: Semen samples from 98 patients underwent high-performance liquid chromatography (HPLC) for GSH/GSSG analysis. A protein assay determined the protein concentration for normalization, and GSH/GSSG redox potentials (Eh) were calculated using the Nernst equation. Results: A significant inverse correlation between GSH/GSSG Eh and sperm count was identified (p = 0.0046 and R2 = 0.071). Analysis also found that cellular GSH concentrations (p < 0.001 and R2 = 0.11) and total GSH (GSH + (GSSG × 2); p = 0.0039 and R2 = 0.074) were significantly and positively correlated with total sperm count, whereas GSSG concentrations were not. The correlation between redox potential and motility was not significantly different (p = 0.11 and R2 = 0.02). Conclusions: This study shows that total sperm count decreases with increasing redox potential, indicating that more oxidized systems, such as the GSH/GSSG system, are associated with lower sperm counts in ejaculated sperm samples. These findings support a potential link between oxidative stress and sperm parameters. As understanding of the relationship between GSH/GSSG Eh and sperm quality improves, this may inform future potential therapies and approaches aimed at supporting male reproductive health.
- 19 May 2025
- Published by MDPI AG in Reproductive Medicine
- Vol. 6 (2) , 13
Open AccessChanges in Sperm Glutathione and Glutathione Redox States Correlate to Poor Sperm Qualitative Measures
Background/Objectives: In the past 50 years, human reproductive capacity has steadily declined with elusive and idiopathic origins. Amongst theorized causes, oxidative stress has been proposed to directly contribute to male infertility. The glutathione (GSH) and glutathione disulfide (GSSG) molecular couple reflect cellular redox environments and are thus reflective of oxidative stress in most cells. Shifting GSH/GSSG redox states to abnormal, more oxidizing conditions can disrupt normal cellular activities. This study explores the correlation between the GSH/GSSG redox system and factors involved in male infertility, including sperm quality, specifically sperm motility and total count. Methods: Semen samples from 98 patients underwent high-performance liquid chromatography (HPLC) for GSH/GSSG analysis. A protein assay determined the protein concentration for normalization, and GSH/GSSG redox potentials (Eh) were calculated using the Nernst equation. Results: A significant inverse correlation between GSH/GSSG Eh and sperm count was identified (p = 0.0046 and R2 = 0.071). Analysis also found that cellular GSH concentrations (p < 0.001 and R2 = 0.11) and total GSH (GSH + (GSSG × 2); p = 0.0039 and R2 = 0.074) were significantly and positively correlated with total sperm count, whereas GSSG concentrations were not. The correlation between redox potential and motility was not significantly different (p = 0.11 and R2 = 0.02). Conclusions: This study shows that total sperm count decreases with increasing redox potential, indicating that more oxidized systems, such as the GSH/GSSG system, are associated with lower sperm counts in ejaculated sperm samples. These findings support a potential link between oxidative stress and sperm parameters. As understanding of the relationship between GSH/GSSG Eh and sperm quality improves, this may inform future potential therapies and approaches aimed at supporting male reproductive health.